Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab (Q57623522)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Heinz Wiendl

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

C Warnke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

O Adams

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

H P Hartung

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Gold

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

B Hemmer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Hohlfeld

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Stangel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

B C Kieseier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1314-1319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00115-011-3319-2

3 February 2020

exact match

0 references

cites work

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Characterization of JC human polyomavirus infection in a Portuguese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-011-3319-2

Seroepidemiology of the human polyomaviruses

21 January 2018

1 reference

12 December 2020

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders

1 reference

12 December 2020

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

1 reference

12 December 2020

Natalizumab dosage suspension: are we helping or hurting?

1 reference

12 December 2020

10.1007/S00115-011-3319-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656322%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference